Experimental drug combo targets Hard-to-Treat head and neck cancer
Disease control
Not yet recruiting
This phase 2 trial tests a combination of two drugs—sacituzumab tirumotecan and an immune checkpoint inhibitor—in people with recurrent or metastatic head and neck squamous cell carcinoma that has progressed after standard therapy. The goal is to see if the combination can shrink…
Phase: PHASE2 • Sponsor: Biying Chen • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC